Last reviewed · How we verify
NCT07162636: E-SEEM
ELECTRICAL STIMULATION AND EXERCISE FOR MUSCLE LOSS IN CIRRHOSIS PATIENTS
NA trial testing NMES+ in Sarcopenia in 112 participants. Not yet recruiting.
30 September 2026
Quick facts
| Lead sponsor | Hospital Universitário Professor Edgard Santos |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 112 |
| Start date | 1 September 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 December 2026 |
Drugs / interventions tested
- NMES+
- NMES -
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
Sponsor
Hospital Universitário Professor Edgard Santos
Who can join
Adults 47 to 70, any sex, with Sarcopenia or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Sarcopenia, whether primary or secondary, substantially impacts the quality of life of patients post-hospital discharge. Compromised functional capacity can lead to a high prevalence of readmissions. In this context, neuromuscular electrical stimulation (NMES), when combined with voluntary contraction (NMES+), emerges as a promising strategy for optimizing muscle strength gain. Objective: To evaluate the efficacy of NMES+ in improving lower limb muscle strength and physical performance in hospitalized sarcopenic individuals with alcoholic cirrhosis. Methods: This is a double-blind, randomized clinical trial. The Intervention Group will undergo NMES+, while the Control Group will perform resistance exercises. The sample will consist of individuals aged 47 to 70 years, diagnosed with sarcopenia through functional tests: handgrip strength and the 5-repetition sit-to-stand test. The protocol will be applied six times per week. Assessments will be conducted at hospital admission and discharge. Data will be analyzed using Student's T-tests for intergroup and intragroup comparisons; Spearman's or Pearson's correlation will assess the association between hospital readmission rates and physical function at hospital discharge. A p-value of 0.05 was set as statistically significant. Expected Results: To observe a statistically significant increase in muscle strength and physical performance in the Intervention Group, and to find a negative correlation between improved physical function and hospital readmission rates. Conclusion: This study is expected to contribute to more effective rehabilitation protocols, improving functionality and reducing hospital readmission in hospitalized patients with alcoholic liver cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07162636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NMES+
Trials testing the same drug.
- NCT05786300 — Effect of NMES+ on Hamstring Lesion (3a/3b) · NA · unknown
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Hospital Universitário Professor Edgard Santos trials
Trials by the same sponsor.
- NCT06011343 — Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis · Phase 2, PHASE3 · unknown
- NCT06616675 — Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropi · Phase 4 · completed
- NCT06449040 — Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly · Phase 1, PHASE2 · completed
- NCT06000514 — Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. · Phase 1, PHASE2 · completed
- NCT03023111 — Miltefosine and GM-CSF in Cutaneous Leishmaniasis · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07162636 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitário Professor Edgard Santos
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07162636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing